Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1738 • 2016 ACR/ARHP Annual Meeting
Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
Peter Nash¹, Iain B McInnes², Philip J Mease³, Ernest H. Choy^4,5, Howard Thom⁶, Chrysostomos Kalyvas⁷, Kunal Gandhi⁸, Shephard Mpofu⁹ and Steffen Jugl⁹, ¹Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ⁶University of Bristol, Bristol, United Kingdom, ⁷MAPI Group, Houten, Netherlands, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. A head-to-head…
Abstract Number: 1680 • 2016 ACR/ARHP Annual Meeting
Apremilast Monotherapy As the First Systemic Treatment in DMARD-Naive Patients with Active Psoriatic Arthritis: 3-Year Treatment Results
Alvin F. Wells¹, Christopher J. Edwards^2,3, Alan J. Kivitz⁴, Paul Bird⁵, Dianne Nguyen⁶, Kamal Shah⁶, Lichen Teng⁶ and Jacob A Aelion⁷, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of Southampton, Southampton, United Kingdom, ³University Hospital Southampton, Southampton, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Summit, NJ, ⁷West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: 1740 • 2016 ACR/ARHP Annual Meeting
Long-Term Improvements in Physical Function of DMARD-Naive and DMARD/Biologic-Experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials
Philip J Mease¹, Alvin F Wells², Jürgen Wollenhaupt³, Stephen Hall⁴, Filip van Den Bosch⁵, Eric Lespessailles⁶, Melissa McIlraith⁷, Dianne Nguyen⁷, Lichen Teng⁷ and Christopher J Edwards⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology & Immunotherapy Center, Franklin, WI, ³Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵UZ Gent, Gent, Belgium, ⁶University of Orléans, Orléans, France, ⁷Celgene Corporation, Summit, NJ, ⁸University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Improving and preserving patient (pt) physical function is an important goal in managing psoriatic arthritis (PsA). Apremilast (APR) has been shown to improve signs…
Abstract Number: 1683 • 2016 ACR/ARHP Annual Meeting
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Renganayaki Pandurengan², Christopher T. Ritchlin⁴, Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The…
Abstract Number: 1743 • 2016 ACR/ARHP Annual Meeting
Prevalence of Inflammatory Neck Pain in a Cohort of Patients with Psoriatic Arthritis and Its Association with Clinical and Radiographic Features
Osvaldo Luis Cerda, Margarita Landi, Cecilia Zaffarana, Josefina Gallino Yanzi, Emilce Schneeberger and Gustavo Citera, Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Cervical inflammatory pain is very common and rarely studied in patients with Psoriatic Arthritis (PsA). The purpose of our study was to evaluate the…
Abstract Number: 1687 • 2016 ACR/ARHP Annual Meeting
Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Laura C. Coates², Catherine L. Shuler³, Chen-Yen Lin³, Susan R. Moriarty³, Chin H. Lee³ and Philip J Mease⁴, ¹Tufts University School of Medicine, Boston, MA, ²University of Leeds, Leeds, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. Ixekizumab (IXE) is an IgG4 mAb that binds…
Abstract Number: 2006 • 2016 ACR/ARHP Annual Meeting
Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study
Mirjam K. de Vries¹, Elizabeth V. Arkema¹, Jerker Jonsson², Judith Bruchfeld³, Lennart TH Jacobsson⁴ and Johan Askling^1,5, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Infectious Diseases Unit, Karolinska University Hospital, The Public Health Agency of Sweden, Stockholm, Sweden, ³Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a well-documented increased risk of tuberculosis (TB) compared to the general population, both with and without treatment…
Abstract Number: 1059 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: There is a known association between conduction disturbances and ankylosing spondylitis (AS). The risk of conduction disturbances in other phenotypes of spondylarthritis (SpA) is…
Abstract Number: 1629 • 2015 ACR/ARHP Annual Meeting
Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Matthias H. Thomas¹, Klaus Krüger², Pee Aries³, Martin Bohl-Buehler⁴, Jan Brandt-Juergens⁵, Verena Rickert⁶ and Siegfried Wassenberg⁷, ¹Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany, ²Praxiszentrum St. Bonifatius, München, Germany, ³Rheumatologie im Struenseehaus, Hamburg, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Praxis Brandt-Juergens/Karberg, Berlin, Germany, ⁶Medical Affairs, MSD Sharp&Dohme GmbH, Haar, Germany, ⁷Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Golimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with accurately selected patients. Data from daily clinical practice in Germany…
Abstract Number: 1715 • 2015 ACR/ARHP Annual Meeting
Sensivity and Specificity of Clinical Criteria to Identify Patients in Ultrasound Remission in Psoriatic Arthritis
Brigitte Michelsen¹, Andreas P Diamantopoulos², Hilde Berner Hammer³, Arthur Kavanaugh⁴ and Glenn Haugeberg^1,5,6, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Haugesund Rheumatism Hospital, Haugesund, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴University of California, San Diego School of Medicine, LaJolla, CA, ⁵Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, ⁶Rheumatology, Martina Hansens Hospital, Gjettum, Norway
Background/Purpose: To date, although several have been proposed, there are no validated remission criteria in psoriatic arthritis (PsA). Validated criteria for minimal disease activity (MDA) in…
Abstract Number: 37 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors
Luis Rodriguez-Rodriguez^1,2, Pedro P Perrotti³, Adrìa Aterido³, Jesús Tornero⁴, Carlos Ferrandiz⁵, Juan D. Cañete⁶, Antonio Fernandez-Nebro⁷, Javier P Gisbert⁸, Eugeni Domènech^9,10, María López-Lasanta³, Sara Marsal³, Benjamín Fernández-Gutiérrez^1,11 and IMID Consortium, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ³Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁴Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ⁵Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁷Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ⁸Gastroenterology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁹Gastroenterology & Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰CIBERehd, Madrid, Spain, ¹¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose : Our aim was 1) to analyze the association between demographic and traditional cardiovascular risk factors (CVRF) and cardiovascular disease (CVD) in subjects affected…
Abstract Number: 1726 • 2015 ACR/ARHP Annual Meeting
Reliability of Radiographic Assessment of Psoriatic Arthritis Mutilans
Dennis Wong¹, Ker-Ai Lee², Richard J. Cook³, Dafna Gladman⁴, Lihi Eder⁴ and Vinod Chandran⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis mutilans (PsAM) is the most severe form of Psoriatic arthritis (PsA). Research on PsAM has been hampered by the lack of an…
Abstract Number: 103 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: Genetic Biomarkers of Psoriatic Spondyloarthritis
Deepak R. Jadon¹, John Bowes², Anne Barton³, Raj Sengupta¹, Alison L Nightingale⁴, Mark Lindsay⁵, Eleanor Korendowych¹, Graham Robinson⁶ and Neil J. McHugh⁷, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ³Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁴Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁶Royal United Hospital, Bath, United Kingdom, ⁷Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: A lack of well-characterised clinical cohorts has impeded research of the genetics of axial disease in psoriatic arthritis (PsA). We sought to determine genetic…
Abstract Number: 2495 • 2015 ACR/ARHP Annual Meeting
Tele-Monitoring of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis
Alexander Langer¹ and Hans-Eckhard Langer², ¹Department of Computer Science, RWTH Aachen University, Aachen, Germany, ²RHIO (Rheumatology, Immunology, and Osteology), Duesseldorf, Germany
Background/Purpose: There is evidence that tight control of rheumatoid arthritis improves outcome. In daily practice this aim is constricted by logistic limitations such as a…
Abstract Number: 165 • 2015 ACR/ARHP Annual Meeting
Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis
Julio Ramírez¹, Jose Inciarte-Mundo², Andrea Cuervo¹, Virginia Ruiz-Esquide², M. Victoria Hernández³, Raimon Sanmarti² and Juan D. Cañete², ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ³Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: We have previously reported that patients with subclinical synovitis defined by synovial hypertrophy grade >2 (SH>2) plus power Doppler (PD) signal had higher disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].